Top Considerations for the Development of Inhaled Biologics

This webcast features: Ashleigh Wake, Business Development Director, Intertek Pharmaceutical Services

Inhaled and nasal biologics continue to grow in importance as advantages presented both by targeted delivery to the lung and systemic delivery for other diseases or treatment pathways are driving this increased attention. In this webinar, Ashleigh Wake describes the top development considerations for inhaled or intranasal biologic analytical development.

These include the need to meet regulatory requirements of ICH Q6B for a well characterized biologic as well as the specific respiratory testing outlined in documents such as the European Medicines Agency (EMA) guideline on the pharmaceutical quality of inhalation and nasal products (June 2006) or the US Food and Drug Administration (FDA) metered dose inhaler (MDI) and dry powder inhaler (DPI) products quality considerations guidance (April 2018).

In addition to specific orally inhaled and nasal drug product (OINDP) tests, Ashleigh will highlight key testing programs to fully characterize the biological entity and establish whether the device delivery mechanism has adversely affected parameters, including structure, purity (higher order structure, aggregation, degradation, etc.), and the activity (potency). She will also touch on strategic formulation and device selection which are necessary to optimize delivery.

This webcast is no longer available.